A Pilot Trial Using Lymphocytes Genetically Engineered with an NY-ESO-1–Reactive T-cell Receptor: Long-term Follow-up and Correlates with Response

Overview of attention for article published in Clinical Cancer Research, March 2015

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (95th percentile)
High Attention Score compared to outputs of the same age and source (94th percentile)

Mentioned by

news: 1 news outlet
blogs: 1 blog
twitter: 9 X users

patent: 96 patents
weibo: 1 weibo user
facebook: 1 Facebook page

Readers on

mendeley: 599 Mendeley

So far, Altmetric has seen 11 X posts from 9 X users, with an upper bound of 119,261 followers.

@MSollender @brendan_49 @Adaptimmune Finally I think I've found the source of your table in this NCI paper describing a different NY-ESO trial NCT00670748 using IL2 from Takara with Kite being mentioned as funding together with NIH and Milstein family …

Pilot Trial Using Lymphocytes Genetically Engineered w/ TCR against NY-ESO-1 Robbins et. al #ClinCanRes #ImmunoOnc http://t.co/rfL6CP8zVh

A Pilot Trial Using Lymphocytes Genetically Engineered with an NY-ESO-1–Reactive T-cell... http://t.co/rR2LzR0rMm

A pilot trial using lymphocytes genetically engineered with an NY-ESO-1-reactive T cell receptor http://t.co/mYuhM1sKxv

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 7 additional X posts.